Divis Laboratories Limited Share Price & Stock Analysis

Divis Laboratories Limited (NSE: DIVISLAB, BSE: 532488) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹3,01,758 Cr, it ranks #31 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 11 in Pharmaceutical CDMO and CRO Services. At ₹11,442.00 (as of 16 Nov 2026), the share price is 3.2% below its 52-week high of ₹11,824.00 and 102.6% above its 52-week low of ₹5,647.50. The share price is up 71.9% over one year and up 34.6% over three months.

Key Metrics

Current Price₹11,442.00
Market Cap₹3,01,758 Cr
NSE SymbolDIVISLAB
BSE Code532488
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Pharmaceutical CDMO and CRO Services
P/E Ratio118.4
Return on Equity16.19%
Return on Assets10.07%
52-Week Range₹5,647.50 – ₹11,824.00
1-Year Price Change+71.9%
3-Month Price Change+34.6%
Beta (1Y)0.21
Dividend Yield0.26%
HeadquartersHyderabad, Telangana
Websitewww.divislabs.com

Latest Quarterly Results — Q2 FY27

Revenue₹3,676 Cr
Net Profit₹1,127 Cr
Net Margin30.7%
EPS (Basic)₹42.49
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Divis Laboratories Limited Quarterly Revenue and Profit Trend

Divis Laboratories Limited reported revenue of ₹3,676 Cr in Q2 FY27, up 35.4% from ₹2,715 Cr in Q2 FY26 and up 19.4% from ₹3,080 Cr in Q1 FY27. It posted a net profit of ₹1,127 Cr for the quarter, against a net profit of ₹689 Cr in Q2 FY26 (up 63.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,410 Cr (Q1 FY26) to ₹3,676 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹3,676 Cr₹1,127 Cr30.7%
Q1 FY27₹3,080 Cr₹902 Cr29.3%
Q4 FY26₹2,831 Cr₹751 Cr26.5%
Q3 FY26₹2,604 Cr₹583 Cr22.4%
Q2 FY26₹2,715 Cr₹689 Cr25.4%
Q1 FY26₹2,410 Cr₹545 Cr22.6%
Q4 FY25₹2,585 Cr₹662 Cr25.6%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 51.88% of Divis Laboratories Limited's shares as of Sept 2026, against 51.89% in Sept 2025 (−0.01 percentage points). Delivery averaged 56.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Divis Laboratories Limited

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Products and Services

1. Segment Adjustment-This segment manufactures and sells active pharmaceutical ingredients and intermediates. 2. Pharmaceuticals-0

Business Segments

1. Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients-100%

Divis Laboratories Limited vs Peers — Pharmaceutical CDMO and CRO Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Divis Laboratories Limited₹3,01,758 Cr118.416.19%₹3,676 Cr+71.9%
Anthem Biosciences Limited₹53,926 Cr90.119.45%₹594 Cr+34.5%
Sai Life Sciences Limited₹40,755 Cr116.115.13%₹659 Cr+120.3%
Onesource Specialty Pharma Limited₹18,138 Crn/m-1.26%₹516 Cr-9.4%
Cohance Lifesciences Ltd₹17,756 Cr100.65.11%₹477 Cr-35.2%
Syngene International Ltd.₹17,630 Cr56.96.62%₹833 Cr-27.9%
Jubilant Pharmova Ltd₹15,556 Cr39.15.96%₹2,370 Cr-14.5%
Concord Biotech Ltd₹12,495 Cr24.213.54%₹309 Cr-14.8%
Blue Jet Healthcare Ltd₹10,140 Cr3819.88%₹376 Cr-9.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Divis Laboratories Limited?

Divis Laboratories Limited is trading at ₹11,442.00, with a market capitalisation of ₹3,01,758 Cr.

Which sector does Divis Laboratories Limited belong to?

Divis Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).

What are the key financial ratios of Divis Laboratories Limited?

Divis Laboratories Limited has a P/E of 118.4 and a return on equity of 16.19%.

What is the stock symbol of Divis Laboratories Limited?

Divis Laboratories Limited is listed on the NSE under the symbol DIVISLAB and on the BSE under the scrip code 532488.

How has Divis Laboratories Limited's share price moved over the past year?

Divis Laboratories Limited's share price is up 71.9% over one year and up 34.6% over three months. Its 52-week range is ₹5,647.50 to ₹11,824.00.

What were Divis Laboratories Limited's latest quarterly results?

In Q2 FY27, Divis Laboratories Limited reported revenue of ₹3,676 Cr and net profit of ₹1,127 Cr, with basic EPS of ₹42.49 (consolidated, parsed from the company's exchange filing).

How have Divis Laboratories Limited's revenue and profit changed over the past year?

Divis Laboratories Limited reported revenue of ₹3,676 Cr in Q2 FY27, up 35.4% from ₹2,715 Cr in Q2 FY26 and up 19.4% from ₹3,080 Cr in Q1 FY27.

What is the promoter holding in Divis Laboratories Limited?

Promoters held 51.88% of Divis Laboratories Limited's shares as of Sept 2026, against 51.89% in Sept 2025 (−0.01 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.